Never miss out on the latest news!
Over 4,000 healthcare professionals have already signed up.
This section looks at the epidemiology and treatment of VTE in paediatric patients
VTE, including DVT and PE, is primarily regarded as an adult disease;1 however, VTE can also affect children.2 Although the overall incidence of VTE in children is low (estimated to be 0.07–0.14 per 10,000 children),3,4 it is around 100–1000 times higher in hospitalized children (occurring in up to 58 cases per 10,000 hospital admissions),5,6 making it a leading cause of hospital-acquired morbidity in this vulnerable patient population.7 The majority of venous thromboembolic events in paediatric patients are reported during infancy and during adolescence.8
More than 90% of venous thromboembolic events in paediatric patients are provoked by underlying medical or surgical factors.3,9,10 This is in contrast to adult patients, in whom up to half of venous thromboembolic events are idiopathic.9 Multiple risk factors have been associated with VTE in paediatric patients,8 and children typically have more than one risk factor at the time of their thrombotic event.7 The single most important risk factor is the presence of a central venous catheter, which doubles the risk of VTE and contributes to >90% of all cases of neonatal VTE and >50% of all cases of VTE in other age groups.9,10
In adults, the primary sites for VTE are the lower limbs (i.e. DVT) and pulmonary arteries (i.e. PE).11 In contrast, in children, VTE location is more variable; other common locations for VTE in paediatric patients (besides the lower limbs and pulmonary arteries) include:3,10,12-14
Location of venous thrombi in children (aged ≥29 days to 18 years) enrolled in the Italian Registry of Thrombosis in Children12
VTE has been associated with a number of adverse clinical outcomes, including mortality and recurrent thrombosis. In a Canadian registry, mortality directly attributable to VTE and recurrent thrombosis occurred in 2.2% and 8.1% of children with VTE, respectively.15 Other chronic complications are influenced by VTE location, and include post-thrombotic syndrome (following DVT), chronic renal insufficiency (following renal vein thrombosis) and neurological deficits (following cerebral sinovenous thrombosis).9,14
Because it is more challenging to conduct clinical trials in children and paediatric VTE is a rare and heterogeneous disease, there was, until recently, a relatively paucity of data from randomized clinical trials evaluating the use of anticoagulants in children.2,10,16
The current standard of care in the management of VTE in paediatric patients usually includes UFH, LMWH and oral VKAs.2,5,17 Real-world data indicate that most children with VTE are treated with LMWH.12,13 Recommendations for dosing and therapeutic range for both heparins and VKAs are derived from adult studies, as well as smaller dose-finding and observational studies in children.2,18 Only two randomized controlled trials assessing heparins/VKAs for the treatment of VTE in children have attempted to enrol >200 children10 – the first, REVIVE, was terminated early due to recruitment problems, and the second, Kids-DOTT, has been running since 2007 and is not estimated to complete until 2022.19-21 (In the setting of prevention of VTE in paediatric patients with LMWH, the recently completed THROMBOTECT trial, supporting the use of enoxaparin for thromboprophylaxis in children with acute lymphoblastic leukaemia during induction therapy, successfully enrolled 949 children whereas the PROTEKT trial closed early after recruitment of 186 of 600 children.10,22,23
NOACs have the potential to overcome some of the limitations of the current standard of care (LMWH/VKAs) for treatment of VTE in paediatric patients.24 All of the NOACs currently approved for the treatment and secondary prevention of recurrent VTE in adults have recently completed (rivaroxaban and dabigatran) or ongoing clinical development programmes (apixaban and edoxaban) assessing their use for the treatment of VTE in paediatric patients.25-35
The EINSTEIN JUNIOR clinical development programme consisted of a phase I study, three phase II studies and onephase III study, enrolling over 650 children across the 5 studies.25,26,28 Together, the phase I and II studies established bodyweight-adjusted rivaroxaban regimens (including an oral suspension) for use in children, matching the rivaroxaban 20 mg once daily dose used in adults.26 The EINSTEIN JUNIOR phase III study recruited 500 children, aged 0–18 years, with acute VTE treated with heparins or fondaparinux, and randomized them (2:1) to receive bodyweight-adjusted rivaroxaban or standard anticoagulation (heparins or fondaparinux alone, or overlapping with and followed by a VKA).25,36
The results of EINSTEIN JUNIOR phase III study were consistent with those from the EINSTEIN programme in adult patients – rivaroxaban-treated children experienced low rates of recurrent VTE without increased risk of bleeding compared with standard anticoagulants. Repeat imaging showed a significantly reduced thrombotic burden with rivaroxaban.36
Recurrent VTE, clinically relevant bleeding and major bleeding in children treated with rivaroxaban or standard anticoagulation in the EINSTEIN JUNIOR phase III study36
The efficacy and safety of dabigatran for the treatment of VTE in children is being investigated in a clinical development programme that includes five studies, including two ongoing phase III studies.30-33 The completed phase II studies, which included 35 patients treated with dabigatran, demonstrated that dabigatran was well tolerated, and the pharmacokinetic/pharmacodynamic relationship in paediatric patients was similar to that seen in adults.30,31,33 Of the ongoing phase III studies, one is comparing dabigatran to standard of care in ~220 children with acute VTE (DIVERSITY study) and the other is a single-arm study assessing the safety of dabigatran for secondary VTE prevention in ~200 children with VTE and persistent VTE risk factors.32,33,37,38 Interim results from both studies suggest that dabigatran is safe and effective for the treatment and secondary prevention of VTE in children.37,38
Guideline recommendations for the treatment of VTE in paediatric patients have been largely based on weak evidence (obtained from adult studies, smaller dose-finding and observational studies in children) and expert opinion.2,5,39 Guidelines on the treatment of VTE in paediatric patients include:
Both sets of guidelines suggest either LMWH or VKAs for the treatment of VTE in paediatric patients. Because the use of VKAs is especially challenging in neonates, the ACCP guidelines suggest to use LMWH or UFH followed by LMWH in neonates.2,5, At the time these guidelines were written, the phase III trials of NOACs for the treatment of VTE in paediatric patients were not completed; consequently, NOACs were not considered as a treatment option in children with VTE.
2012 ACCP guideline recommendations for the treatment of VTE in neonates (birth–28 days)2
2012 ACCP guideline recommendations for the treatment of VTE in children (28 days–18 years)2